https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Thus, AA-SRF can be further studied for use as a safe alternative adjuvant in vaccines. To verify glomerular PLA2R antigen and serum PLA2R antibody expression in membranous nephropathy as well as to explore glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy (IMN) in the background of different serum anti-PLA2R levels. We retrospectively analyzed 155 patients who were diagnosed with IMN by kidney biopsy. Patients were divided into six groups according to their serum PLA2R antibody or g
Curtir
Comentario
Compartilhar
